Our previous studies identified Hsp70-Bim PPI as a CML-specific target and it protects resistant CML cells through recruitment of specific oncogenic clients [17, 18]. Here, BCL2L11 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.